Objective: To characterize the AD burden in adult patients relative to both matched non-AD controls and matched patients with psoriasis in terms of comorbidities, health care resource utilization (HCRU), and costs.
Atopic dermatitis (AD) is a chronic relapsing, inflammatory skin disease characterized by pruritus, xerosis, and eczematous lesions and with features including erythema, infiltration/papulation, excoriations, and lichenification. 1 Although AD most often starts in early infancy or childhood, 2,3 a recent study reported that childhood AD extended into adult life in approximately half of the cases studied. 4 For many patients, moderate/severe AD is a chronic, lifelong condition that is underrecognized as a major public health concern. 2, 3, 5 Recent publications have documented the multidimensional disease burden in patients with moderate/severe AD, encompassing increased levels of itch, pain, sleep disturbance, anxiety and depression, and impaired health-related quality of life. [6] [7] [8] [9] In addition to the disease burden, AD is associated with a substantial economic burden. Costs incurred by patients, their families, and payers include physician visits, emergency room (ER) visits, hospitalizations, prescriptions, and over-the-counter treatments. 10 However, comprehensive data on the disease and economic burden of AD relative to the general adult population and other chronic skin disorders are limited. To this end, the aim of the present study was to evaluate the real-world patient burden, in terms of comorbidities, health care resource utilization (HCRU), and costs, in adults with AD relative to both adults without AD and adults with psoriasis on the basis of data from the 2013 National Health and Wellness Survey (NHWS). An additional aim was to evaluate the impact of AD severity on these outcomes.
METHODS

Data source
Patient-level data were obtained from the 2013 US NHWS, an Internet-based general population survey. 11 The NHWS uses a random stratified sampling framework (sex, age, and race/ethnicity) to ensure that it is representative of the demographic composition of the US adult population, based on data from the US Bureau of the Census. A total of 1,183,287 individuals were asked to complete the 2013 NHWS, 109,592 of whom (9.3%) responded. Of the responders, 75,000 (68.4%) met the inclusion criterion (age $18 years), completed the survey, and gave informed consent for their anonymized data to be used for research purposes. The NHWS was approved by the Essex Institutional Review Board (Lebanon, NJ). 9 
Patient population
The AD cohort comprised adult respondents who indicated that they had experienced AD in response to the question: ''Which of the following conditions have you experienced in the past 12 months?'' Possible response options were to select all conditions that applied, select ''I have not experienced any of the above conditions in the past 12 months,'' and select ''I decline to answer.'' In addition, respondents had to answer yes to the question ''Has your AD been diagnosed by a physician?''
The non-AD control cohort comprised adult respondents who did not report experiencing AD, dermatitis, or eczema in the past 12 months. The psoriasis cohort comprised adult respondents who indicated that they had experienced psoriasis in response to the question: ''Which of the following conditions have you ever experienced?'' Possible response options were to select all conditions that applied, select ''I do not have any of the above conditions,'' and select ''I decline to answer.'' In addition, respondents had to answer yes to the question ''Has your psoriasis been diagnosed by a physician?'' Respondents who reported a diagnosis of both AD and psoriasis were excluded from this analysis.
Adults with AD graded their disease severity (mild, moderate, or severe) in response to the question ''How severe is your dermatitis/eczema?'' Adults with psoriasis graded their disease severity in response to the question ''According to the National Psoriasis Foundation, the palm of the hand equals 1% of the skin. Thinking about this, please estimate the percent of your body surface your psoriasis currently affects as follows: mild (\3% body coverage); moderate (3%-10% body coverage); or severe ([10% body coverage).''
Propensity score matching
To correct for potential confounding, the AD cohort was propensity scoreematched 12 to non-AD
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controls (1:2) and to patients with psoriasis (1:1 [because of a much smaller AD-to-psoriasis respondent ratio]). The matching variables comprised those variables that were statistically different between the groups at baseline and during iterations of the propensity matching process. Relevant variables were entered into a logistic regression model using the SAS/STAT Ò LOGISTIC (SAS Institute, Inc, Cary, NC) procedure to generate the propensity score. Matching was completed by using the ''greedy matching'' technique. The algorithm proceeds with making the best matches first, and the next-best matches next, and so on in a hierarchical sequence until no more matches can be made. Best matches are those with the highest-digit match on propensity score (5 decimal points). The algorithm proceeds sequentially to the lowest-digit match on propensity score (0 decimal points). Goodness of matched pairs were defined as those with the least absolute difference in matched propensity score. For AD versus non-AD matching, each AD patient was matched with 2 non-AD controls using a 1:2 matching algorithm. For AD versus psoriasis matching, a 1:1 matching algorithm was used. Propensity score matching of patients with AD and non-AD controls was based on the variables age, sex, ethnicity, education, income, insurance status, alcohol consumption, exercise behavior, and Charlson Comorbidity Index (CCI). 13 Propensity score matching of patients with AD and patients with psoriasis was based on age, sex, ethnicity, education, employment status, body mass index, insurance status, smoking status, exercise behavior, CCI, and self-rated disease severity (moderate/ severe or mild). After matching, matching variables were re-examined between the matched groups to confirm matching.
Comorbidities
The CCI was used to evaluate the overall comorbidity burden. 13 The self-reported prevalence of arthritis (including osteoarthritis, rheumatoid arthritis, and psoriatic arthritis), atopic-related comorbidities (asthma and hay fever/nasal allergies), hypertension, high cholesterol level, and osteoporosis/osteopenia was evaluated on the basis of respondents' answers to the questions ''Which of the following conditions have you experienced in the past 12 months?'' or ''Which of the following conditions have you ever experienced'' and ''Has your condition been diagnosed by a physician?''
HCRU
HCRU was defined by the number of visits to a health care provider in the past 6 months (''How many visits did you make to the following traditional health care provider(s) in the past 6 months?''), ER visits (''How many times have you been to the ER for your own medical condition in the past 6 months?''), and hospitalizations (''How many times have you been hospitalized for your own medical condition in the past 6 months?'').
Direct costs were estimated using data stratified according to age from the Medical Expenditure Panel Survey 2012.
14 For each respondent, the number of each type of visit in the last 6 months was multiplied by 2 to extrapolate to the annual number of visits and then multiplied by its average cost (Supplemental Table I ; available at http://www.jaad.org).
Analyses
The prevalence of comorbidities, HCRU, and costs were analyzed in patients with AD against matched non-AD controls and against matched patients with psoriasis. In addition, these outcomes were examined in the moderate/severe AD cohort versus in the mild AD cohort. A chi-square test or the t test were used to compare differences between groups for categorical or continuous variables, respectively, with the 2-tailed significance level (a) set at .05. A sensitivity analysis of direct cost data was carried out by calculating least squares mean costs after adjusting for the presence of asthma and nasal allergies/hay fever. Analyses were performed with SAS software, version 9.3 (SAS Institute, Inc).
RESULTS
AD versus non-AD and moderate/severe versus mild AD Demographics. Demographic characteristics in patients with AD and matched non-AD controls are shown in Table I . The analysis cohort of 1047 adults (mean age, 46.1 years; 68.3% female and 66.8% non-Hispanic white) comprised 349 patients with AD and 698 matched non-AD controls. Self-rated disease severity was available for 306 patients with AD, of whom 52.3% reported moderate (42.8%) or severe (9.5%) disease and 47.7% reported mild disease. Overall, demographic characteristics and CCI score were generally similar between patients HCRU and costs. Compared with non-AD controls, patients with AD reported using significantly more health care resources (Table III) . Mean (SD) health care provider visits were 6.6 (9.8) versus 3.9 (5.4) (P \ .001). The number of ER visits and hospitalizations was more than twice that in non-AD controls. In patients with AD, the mean (SD) number of ER visits was 0.5 (1.2) versus 0.2 (0.8) (P \ .001) and the mean (SD) number of hospitalizations was 0.3 (1.0) versus 0.1 (0.7) (P = .004). Patients with moderate/severe AD used numerically greater resources than patients with mild AD; however, none of the differences were statistically significant.
In accordance with the HCRU data, patients with AD incurred significantly higher costs than non-AD controls across all evaluated categories (Table III) . Thus, the total mean (SD) annual per patient direct costs in patients with AD were $9782 higher than those of non-AD controls: $24,401 ($37,355) versus $14,619 ($29,799) (P \ .001). Controlling for the presence of asthma and nasal allergies/hay fever reduced the difference between AD and non-AD in total mean direct costs to $7901 (P = .001) (Table III) . Patients with moderate/severe AD incurred numerically higher costs than did patients with mild AD across the evaluated categories. Controlling for the presence of asthma and nasal allergies/hay fever increased the difference between moderate/severe versus mild AD in total mean direct costs from $3757 to $5522. None of the differences were statistically significant (Table III) .
AD versus psoriasis
Demographics. The analysis cohort comprised 260 patients with AD and 260 matched patients with psoriasis. Demographic characteristics were similar between the 2 groups (Table IV) .
Comorbidities. The self-reported prevalence of comorbidities in patients with AD versus matched patients with psoriasis are presented in Table V . Compared with patients with psoriasis, patients with AD had significantly higher odds of reporting asthma (OR, 1.7; 95% CI, 1.1-2.7; P = .01) and nasal allergies/hay fever (OR, 2.3; 95% CI, 1.6-3.2; P \ .001). Conversely, patients with psoriasis had higher odds of developing hypertension (OR, 0.7; 95% CI, 0.5-1.0; P = .03).
HCRU and costs. HCRU in patients with AD versus in matched patients with psoriasis is shown in Table VI . Although the number of visits was low, the mean (SD) number of ER visits required by patients with AD in the past 6 months was significantly higher than that of patients with psoriasis: 0.5 (1.1) versus 0.3 (1.0) (P = .02). Accordingly, mean (SD) annual per patient ER visit costs incurred by patients with AD were almost twice those of patients with psoriasis: $1448 ($3421) versus $750 ($3008) (P = .01). The number of hospitalizations and hospitalization costs were also higher in patients with AD, but these differences did not attain statistical significance.
DISCUSSION
To improve the morbidity associated with AD in adults, it is necessary to characterize its disease burden in the general population. This comparative analysis of comorbidities, HCRU, and costs indicates that US adult patients with AD have a significantly increased risk for reporting atopic comorbidities such as asthma and nasal allergies/hay fever compared with matched non-AD controls. The association between AD and atopic comorbid conditions has been recognized previously [15] [16] [17] and is consistent with the prevailing concept of the Table III . AD, Atopic dermatitis; CI, confidence interval; ER, emergency room; HCRU, health care resource utilization; LS, least squares; SD, standard deviation. *Direct costs were adjusted for the presence of asthma and nasal allergies/hay fever.
''atopic march'' from AD to other common allergic conditions.
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In accordance with the high comorbidity burden in patients with AD, HCRU was significantly higher in the AD cohort compared with non-AD controls for all categories evaluated. The difference was largely driven by health care provider visits and associated costs. Although the numbers of reported hospitalizations and ER visits were small, the utilization of these categories by patients with AD was approximately twice that reported by non-AD controls. Overall, mean annual per patient total direct costs in patients with AD were approximately $10,000 higher than those of non-AD controls ($24,401 vs $14,619). Controlling for the presence of asthma and nasal allergies/hay fever reduced the AD versus non-AD difference in total mean direct costs by approximately 20%, which is in accordance with the higher atopic burden in patients with AD. [15] [16] [17] Patients with more severe AD have been shown to be at a higher risk for atopic comorbidities. 19 Also, they are generally associated with significantly higher all-cause HCRU and costs relative to less severe AD. 20, 21 The nonsignificant differences between severity levels in this study were likely due to insufficient statistical power to detect small differences in outcomes between the moderate/ severe and mild subgroups. It is important to note that more than 80% of the patients in the moderate/ severe group reported their disease as moderate. Thus, the comparative analysis of burden according to severity was predominantly that between patients with moderate disease and those with mild disease, which partly explains why the differences are not larger. An additional factor that may have had an influence on the severity analyses was that severity was patient rated and the level of concordance between patient-and physician-rated severity was not assessed in the current study. Previous studies have reported significant differences between patient-and physician-rated severity in adult patients. 22, 23 These results highlight the need for objective assessment of AD severity in patient self-report surveys through validated instruments, such as the Patient-Oriented Severity Scoring of Atopic Dermatitis, 24 or the Patient Oriented Eczema Measure. 25 The present analysis and the companion article in this issue of the Journal of the American Academy of Dermatology (Eckert et al) are, to the best of our knowledge, the first publications to provide comparative data on the disease burden in adults for AD and psoriasis. Like AD, psoriasis is a common inflammatory skin disease, with a prevalence in adults of about 3%. [26] [27] [28] Patients with chronic plaque psoriasis, the most common form of the disease (about 90% of cases), present with itching and erythematous plaques covered by silver lamellar scales. 29 Psoriasis is associated with impairments in health-related quality of life and an excess risk for cardiometabolic disease and mortality, especially in patients with more severe disease. [30] [31] [32] [33] [34] [35] Our analyses of NHWS real-world data indicate that patients with AD have a significantly higher risk for atopic comorbidities than do patients with psoriasis. With regard to HCRU, the numbers of hospitalizations and ER visits of patients with AD were approximately double those reported by patients with psoriasis. Interestingly, patients with psoriasis reported higher rates of hypertension, confirming the different cardiovascular risk profile compared with AD.
A strength of this study is that the NHWS is representative of the demographic composition of the US adult population, and thus, the results presented here are likely to be applicable to the wider population of US adult patients with AD. Propensity score matching of patients with AD and non-AD controls, which was carried out in an effort to minimize confounding due to demographic characteristics, was an additional strength of this study. The inherent limitation of the study is that patient-reported data are susceptible to recall bias 36 and erroneous classification, given that such data are not independently verified against clinical records. However, these errors would be expected to be nondifferential and thus unlikely to mask differences in burden between groups. Furthermore, we matched our cohorts on the basis of numerous factors to minimize the potential for confounding to affect the results, with the caveat that overmatching can result in the masking of true associations. 37 The NHWS does not include data on key AD-and psoriasis-specific outcome measures, such as itch and pain; nor does it allow the clinical evaluation of AD severity using SCORAD 24 or psoriasis severity using the Simplified Psoriasis Index. 38 An additional limitation is that HCRU data could not be definitively attributed to AD or psoriasis because claims specifically linking resource use with these conditions are not captured by the NHWS database.
CONCLUSIONS
The results from this analysis indicate that adult patients with AD experience a substantial patient burden relative to matched controls without AD, as is evidenced by a significantly increased risk for development of atopic conditions (asthma and hay fever/nasal allergies) and arthritis, as well as increased HCRU and associated costs. Adult patients with AD reported a significantly higher prevalence of atopic conditions and a significantly increased number of ER visits and associated costs relative to matched patients with psoriasis, whereas psoriasis was associated with a greater prevalence of hypertension. Taken together, these data suggest a significant need for enhanced treatment options for patients with AD.
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